Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16204287rdf:typepubmed:Citationlld:pubmed
pubmed-article:16204287lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0232804lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0002986lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0542559lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C1552411lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0962517lld:lifeskim
pubmed-article:16204287lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:16204287pubmed:issue2lld:pubmed
pubmed-article:16204287pubmed:dateCreated2006-1-19lld:pubmed
pubmed-article:16204287pubmed:abstractTextFabry disease is an X-linked disorder of glycosphingolipid catabolism that is the result of an intracellular deficiency in the lysosomal enzyme alpha-galactosidase A (alpha-Gal A). This enzymatic defect results in the accumulation of globotriaosylceramide (Gb(3)) within cells and causes progressive neurological, cardiovascular and renal dysfunction. Our objective is to describe the safety and renal effects of long-term enzyme replacement therapy.lld:pubmed
pubmed-article:16204287pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16204287pubmed:languageenglld:pubmed
pubmed-article:16204287pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16204287pubmed:citationSubsetIMlld:pubmed
pubmed-article:16204287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16204287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16204287pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16204287pubmed:statusMEDLINElld:pubmed
pubmed-article:16204287pubmed:monthFeblld:pubmed
pubmed-article:16204287pubmed:issn0931-0509lld:pubmed
pubmed-article:16204287pubmed:authorpubmed-author:SchiffmannRap...lld:pubmed
pubmed-article:16204287pubmed:authorpubmed-author:BradyRoscoe...lld:pubmed
pubmed-article:16204287pubmed:authorpubmed-author:RiesMarkusMlld:pubmed
pubmed-article:16204287pubmed:authorpubmed-author:TimmonsMargar...lld:pubmed
pubmed-article:16204287pubmed:authorpubmed-author:FlahertyJohn...lld:pubmed
pubmed-article:16204287pubmed:issnTypePrintlld:pubmed
pubmed-article:16204287pubmed:volume21lld:pubmed
pubmed-article:16204287pubmed:ownerNLMlld:pubmed
pubmed-article:16204287pubmed:authorsCompleteYlld:pubmed
pubmed-article:16204287pubmed:pagination345-54lld:pubmed
pubmed-article:16204287pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:meshHeadingpubmed-meshheading:16204287...lld:pubmed
pubmed-article:16204287pubmed:year2006lld:pubmed
pubmed-article:16204287pubmed:articleTitleLong-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.lld:pubmed
pubmed-article:16204287pubmed:affiliationDevelopmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke National Institutes of Health, Bethesda, MD 20892-1260, USA. rs4e@nih.govlld:pubmed
pubmed-article:16204287pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16204287pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:16204287pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16204287lld:pubmed